{
    "clinical_study": {
        "@rank": "116145", 
        "arm_group": [
            {
                "arm_group_label": "AndroGel", 
                "arm_group_type": "Active Comparator", 
                "description": "AndroGel (testosterone gel) 1.62% Metered-Dose Pump. One actuation 20.25 mg"
            }, 
            {
                "arm_group_label": "Testosterone Gel", 
                "arm_group_type": "Experimental", 
                "description": "Testosterone Topical Gel, 1.62% Metered Pump. One actuation of 20.25 mg."
            }
        ], 
        "brief_summary": {
            "textblock": "Bioequivalence study comparing the rate and extent of testosterone absorption for a test\n      formulation versus the reference product."
        }, 
        "brief_title": "Bioequivalence Study of Test and Reference Testosterone Topical Gel, 1.62% Metered Pump in Testosterone Deficient Adult Male Subjects Under Fasting Conditions", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Primary Hypogonadism", 
            "Hypogonadotropic Hypogonadism"
        ], 
        "condition_browse": {
            "mesh_term": "Hypogonadism"
        }, 
        "detailed_description": {
            "textblock": "To compare the rate and extent of testosterone absorption for a test formulation of\n      Testosterone Topical Gel, 1.62% Metered Pump, manufactured  with that of AndroGel\u00ae\n      (testosterone gel) 1.62% Metered-Dose Pump, in normal, healthy, adult,\n      testosterone-deficient (hypogonadal) human male subjects  under fasting conditions."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy adult men with hypogonadism with testosterone levels <250ng/dL\n\n          -  18 to 65 years of age (inclusive)\n\n          -  Have normal PSA < 4.0ng/mL\n\n          -  Weighing a minimum of 50 kg and having a body mass index between 18.0 and 38.0 kg/m2.\n\n          -  Good health as determined by medical history and lack of clinically significant\n             abnormalities (other than hypogonadism).\n\n          -  Vital signs,  must be within the following ranges  heart rate: 45-100 bpm; systolic\n             BP: 90-150 mmHg; diastolic BP: 50-90 mmHg. Out-of-range vital signs may be repeated.\n\n        Exclusion Criteria:\n\n          -  Is female\n\n          -  History of allergy or sensitivity to AndroGel\u00ae or any component of drug or a related\n             testosterone drug, Axiron\u00ae, Testim\u00ae, etc.\n\n          -  History of allergy or intolerance to soy, soybean, and/or soy lecithin\n\n          -  History of any drug or food hypersensitivity or intolerance which, would compromise\n             the safety of the subject or the study.\n\n          -  History or presence of clinically significant ocular, cardiovascular, pulmonary,\n             hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic,\n             neurologic, oncologic, or psychiatric disease or any othercondition that, would\n             jeopardize the safety of the subject or the validity of the study results.\n\n          -  Had no major surgery or illness within 3 months before screening.\n\n          -  History or presence of benign prostate hypertrophy, prostate and/or breast cancer.\n\n          -  Has tattooed, damaged, scarred skin or any skin condition on right or left upper arm\n             and shoulder region that may affect absorption of drug.\n\n          -  Has a clinically significant abnormal finding on the physical exam, medical history,\n             electrocardiogram or clinical laboratory results at screening.\n\n          -  Has been on a significantly abnormal diet during the 4 weeks preceding the first dose\n             of study medication.\n\n          -  Has donated blood within 56 days or plasma within 30 days prior to the first dose of\n             study medication.\n\n          -  Has participated in another clinical trial within 30 days prior to the first dose of\n             study medication.\n\n          -  Has used any over-the-counter  medication, including nutritional supplements, within\n             7 days prior to the first dose of study medication.\n\n          -  Has used any prescription medication including hormonal treatment and or supplement\n             within 30 days prior to the first dose of study medication.\n\n          -  No depot injections or drug implants within 3 months of first dose of study\n             medication.\n\n          -  Has been treated with any known drugs that are moderate or strong inhibitors/inducers\n             of CYP enzymes such as barbiturates, phenothiazine, cimetidine, carbamazepine, etc.,\n             within 30 days prior to the first dose of study medication and that may impact\n             subject safety or the validity of the study results.\n\n          -  Has positive cotinine test and/or smoked or used tobacco products within 60 days\n             prior to the first dose of study medication\n\n          -  Has a positive urine screen for drugs of abuse\n\n          -  Has positive alcohol breathalyzer test\n\n          -  Has a positive test for Hepatitis B surface antigen, Hepatitis C antibody, or Human\n             Immunodeficiency Virus (HIV) at screening or has been previously treated for\n             Hepatitis B, Hepatitis C, or HIV infection.\n\n          -  Any difficulty fasting or has any dietary restrictions such as lactose intolerance,\n             vegan, low-fat, etc.\n\n          -  Unavailable for any confinement days or scheduled visits."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02110368", 
            "org_study_id": "AL1401"
        }, 
        "intervention": [
            {
                "arm_group_label": "Testosterone Gel", 
                "intervention_name": "Testosterone Topical Gel, 1.62% Metered Pump", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "AndroGel", 
                "intervention_name": "AndroGel (testosterone gel) 1.62% Metered-Dose Pump", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Testosterone", 
                "Testosterone enanthate", 
                "Testosterone undecanoate", 
                "Testosterone 17 beta-cypionate", 
                "Methyltestosterone"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 28, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Miami Gardens", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "33169"
                }, 
                "name": "Phase One Solutions, Inc."
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open-Label, Randomized, Balanced, Single-Dose, Two Treatment, Four Period, Two Sequence Replicate Design, Bioequivalence Study Of Testosterone Topical Gel, 1.62% Metered Pump, Manufactured By Amneal Pharmaceuticals LLC With AndroGel (Testosterone Gel) 1.62% Metered-Dose Pump, Marketed By Abbvie Inc., In Testosterone-Deficient (Hypogonadal) Adult Male Subjects Under Fasting Conditions", 
        "overall_official": {
            "affiliation": "Phae 1 Solutions", 
            "last_name": "Lawrence Galitz, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Area under the concentration vs. time curve, from the time of first dosing to the time of the last measured concentration.", 
                "measure": "AUC0-t", 
                "safety_issue": "No", 
                "time_frame": "Pre-Deose: -1 hour, -0.5 hour and Post-Dose 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 32, 36, 40, 48, and 60 hours"
            }, 
            {
                "description": "Area under the concentration vs. time curve, from time of first dosing to infinity", 
                "measure": "AUC0-inf", 
                "safety_issue": "No", 
                "time_frame": "Pre-Deose: -1 hour, -0.5 hour and Post-Dose 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 32, 36, 40, 48, and 60 hours"
            }, 
            {
                "description": "Maximum reported concentration. Estimated for both baseline", 
                "measure": "Cmax", 
                "safety_issue": "No", 
                "time_frame": "Pre-Deose: -1 hour, -0.5 hour and Post-Dose 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 32, 36, 40, 48, and 60 hours"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02110368"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Time at which Cmax is first observed", 
                "measure": "Tmax", 
                "safety_issue": "No", 
                "time_frame": "Pre-Deose: -1 hour, -0.5 hour and Post-Dose 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 32, 36, 40, 48, and 60 hours"
            }, 
            {
                "description": "Apparent first order terminal elimination rate constant determined from the terminal log-linear concentration-time data", 
                "measure": "Kel", 
                "safety_issue": "No", 
                "time_frame": "Pre-Deose: -1 hour, -0.5 hour and Post-Dose 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 32, 36, 40, 48, and 60 hours"
            }, 
            {
                "description": "Terminal elimination half-life", 
                "measure": "T 1/2", 
                "safety_issue": "No", 
                "time_frame": "Pre-Deose: -1 hour, -0.5 hour and Post-Dose 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 32, 36, 40, 48, and 60 hours"
            }
        ], 
        "source": "Amneal Pharmaceuticals, LLC", 
        "sponsors": {
            "collaborator": {
                "agency": "Phase One Solutions, Inc.", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Amneal Pharmaceuticals, LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}